Cargando…

Author Correction: 3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib

Detalles Bibliográficos
Autores principales:	Meraz, Ismail M., Majidi, Mourad, Fang, Bingliang, Meng, Feng, Gao, Lihui, Shao, RuPing, Song, Renduo, Li, Feng, Lissanu, Yonathan, Chen, Huiqin, Ha, Min Jin, Wang, Qi, Wang, Jing, Shpall, Elizabeth, Jung, Sung Yun, Haderk, Franziska, Gui, Philippe, Riess, Jonathan Wesley, Olivas, Victor, Bivona, Trever G., Roth, Jack A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Author Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244399/ https://www.ncbi.nlm.nih.gov/pubmed/37280434 http://dx.doi.org/10.1038/s42003-023-04979-9

Ejemplares similares

3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib
por: Meraz, Ismail M., et al.
Publicado: (2023)

Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer
por: Wu, Wei, et al.
Publicado: (2017)

TUSC2 immunogene enhances efficacy of chemo-immuno combination on KRAS/LKB1 mutant NSCLC in humanized mouse model
por: Meraz, Ismail M., et al.
Publicado: (2022)

Mirror image phosphoinositides regulate autophagy
por: Vicinanza, Mariella, et al.
Publicado: (2015)

TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin
por: Xiaobo, Cao, et al.
Publicado: (2016)

Author Correction: Phosphoinositides regulate the TCR/CD3 complex membrane dynamics and activation
por: Chouaki Benmansour, Nassima, et al.
Publicado: (2020)

Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer
por: Poels, Kamrine E., et al.
Publicado: (2022)

EGFR targeted therapy resistance: current status, challenges, and future outlook
por: Bivona, Trever G.
Publicado: (2020)

Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
por: Chmielecki, Juliann, et al.
Publicado: (2023)

Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients
por: Lin, Luping, et al.
Publicado: (2012)

Adaptive stress signaling in targeted therapy resistance in cancer
por: Pazarentzos, Evangelos, et al.
Publicado: (2015)

Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
por: Neel, Dana S., et al.
Publicado: (2017)

Targeting AXL in NSCLC
por: Zaman, Aubhishek, et al.
Publicado: (2021)

Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancer
por: Manabe, Tadashi, et al.
Publicado: (2022)

Quantitative Framework for Bench-to-Bedside Cancer Research
por: Zaman, Aubhishek, et al.
Publicado: (2022)

The Tumor Suppressor Gene TUSC2 (FUS1) Sensitizes NSCLC to the AKT Inhibitor MK2206 in LKB1-dependent Manner
por: Meng, Jieru, et al.
Publicado: (2013)

Author Correction: Phosphoinositide 3-Kinase (PI3K) Subunit p110δ Is Essential for Trophoblast Cell Differentiation and Placental Development in Mouse
por: Hu, Xiwen, et al.
Publicado: (2020)

AXL receptor tyrosine kinase as a therapeutic target in NSCLC
por: Okimoto, Ross A, et al.
Publicado: (2015)

Targeting Oncogenic BRAF: Past, Present, and Future
por: Zaman, Aubhishek, et al.
Publicado: (2019)

TAPO in first‐line osimertinib therapy and continuation of osimertinib
por: Mimura, Chihiro, et al.
Publicado: (2022)

Long Non-Coding RNAs as Emerging Targets in Lung Cancer
por: Gencel-Augusto, Jovanka, et al.
Publicado: (2023)

Understanding Drug Sensitivity and Tackling Resistance in Cancer
por: Tyner, Jeffrey W., et al.
Publicado: (2022)

Dysregulation of Phosphoinositide 5-Phosphatases and Phosphoinositides in Alzheimer's Disease
por: Ando, Kunie, et al.
Publicado: (2021)

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers
por: Nichols, Robert J., et al.
Publicado: (2018)

Author Correction: Identification of potentially functional modules and diagnostic genes related to amyotrophic lateral sclerosis based on the WGCNA and LASSO algorithms
por: Daneshafrooz, Narges, et al.
Publicado: (2023)

Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics
por: Gentile, Emanuela, et al.
Publicado: (2017)

Phosphoinositides and phagocytosis
por: Gillooly, David J., et al.
Publicado: (2001)

Mechanisms of resistance to osimertinib
por: Lazzari, Chiara, et al.
Publicado: (2020)

Osimertinib-Induced Cardiomyopathy
por: Patel, Shruti R., et al.
Publicado: (2020)

Osimertinib‐related liver injury with successful osimertinib rechallenge: A case report
por: Cheng, Yuan‐Ling, et al.
Publicado: (2022)

Therapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells
por: Pataer, Apar, et al.
Publicado: (2019)

Phosphoinositides and Receptor Mechanisms
por: Jen, Joanna
Publicado: (1987)

Phosphoinositides as membrane organizers
por: Posor, York, et al.
Publicado: (2022)

TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC)
por: Cao, Xiaobo, et al.
Publicado: (2017)

Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC
por: Lara, Matthew S., et al.
Publicado: (2022)

Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma
por: Satoh, Shingo, et al.
Publicado: (2017)

Successful Osimertinib Rechallenge with Steroid Therapy after Osimertinib-induced Interstitial Lung Disease
por: Kiriu, Tatsunori, et al.
Publicado: (2017)

Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
por: Saito, Zentaro, et al.
Publicado: (2023)

Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells
por: Li, Hongyu, et al.
Publicado: (2015)

Osimertinib: Pneumonitis: case report
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c5l7vka4gas4sbf5bj8jhop11r